Allurion Technologies Revenue

In the year 2025, Allurion Technologies had annual revenue of $15.23M, down -52.57%. Allurion Technologies had revenue of $3.61M in the quarter ending December 31, 2025, a decrease of -35.38%.

Revenue

15.23M

Revenue Growth

-52.57%

P/S Ratio

0.73

Revenue / Employee

380.75K

Employees

Market Cap

11.11M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	15.23M	-16.88M	-52.57%
Dec 31, 2024	32.11M	-21.36M	-39.94%
Dec 31, 2023	53.47M	-10.74M	-16.73%
Dec 31, 2022	64.21M	25.97M	67.91%
Dec 31, 2021	38.24M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
ALR Technologies SG	25.54K
QHSLab	2.69M
REMSleep Holdings	16.72K
Guided Therapeutics	767.00K
BioElectronics	1.61M
Ludwig Enterprises	207.00
Biotricity	15.45M
Kelyniam Global	2.67M

Revenue Rankings

Allurion Technologies News

8 days ago - Allurion Treats First Commercial Patients in the United States, Marking Major Milestone - Business Wire
6 weeks ago - Allurion Advances Plan to Regain Listing Compliance - Business Wire
6 weeks ago - Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy - Business Wire
7 weeks ago - NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR) - Business Wire
2 months ago - Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE - Business Wire
2 months ago - Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds - Business Wire
2 months ago - Allurion Receives U.S. FDA Approval - Business Wire
3 months ago - Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices - Business Wire

More News